

Do you have diabetic macular edema (DME)?

A clinical trial for people with DME underrepresented in research studies

DME is the leading cause of vision loss in patients with diabetes. Certain populations have been historically underrepresented in clinical trials, including DME trials.

Underrepresented populations in DME clinical trials include those who self-identify as Black/African American, Hispanic/Latino American, or Native American/Alaska Native/Native Hawaiian or other Pacific Islander.

Population diversity in clinical trials is important to make sure we know how study treatments work for people of all different backgrounds. The purpose of the Elevatum study is to expand understanding of how faricimab, an FDA-approved medicine for DME, can help adults from underrepresented populations with DME who have not received treatment.

Site Contact Information:



Talk to your doctor for more information on the Elevatum study.